Search company, investor...

About Elevation Biotech

Elevation Biotech specialises in the design and discovery of small peptide and peptidomimetic HIV attachment inhibitors. The company have developed biochemical and virological in vitro assays that screen specifically for the ability of compounds to block or interfere with viral attachment to the cell surface receptor CD4. The company's lead compound, is a short 7 amino acid peptide that binds to HIV envelope protein gp120 thereby preventing attachment of virus to the CD4 molecule.

Headquarters Location

South Africa



Elevation Biotech Frequently Asked Questions (FAQ)

  • Who are Elevation Biotech's competitors?

    Competitors of Elevation Biotech include Trellis Bioscience, BioMarck Pharmaceuticals, Dyax, Alios BioPharma, TaiGen Biotechnology and 7 more.


Compare Elevation Biotech to Competitors

Severn Biotech Logo
Severn Biotech

Severn Biotech is a company focused on the manufacturing of biotechnology products within the microbiology sector. The company specializes in peptide synthesis chemistry and immunology conjugates, offering a range of laboratory reagents and chemical products. Severn Biotech provides bespoke reagents, OEM manufacturing, and custom solutions, adhering to strict quality assurance protocols and ISO standards. It is based in United Kingdom.

Oligomerix Logo

Oligomerix is a biotechnology company that focuses on the development of disease-modifying therapeutics for neurodegenerative diseases, specifically those characterized by aberrant tau protein. The company's main offerings include small molecule inhibitors that target the tau aggregation cascade and its progression, aiming to treat conditions ranging from rare tauopathies to Alzheimer's disease. The company primarily serves the healthcare sector, particularly in the area of neurodegenerative diseases. It was founded in 2006 and is based in West Harrison, New York.

Biolog Logo

Biolog is a company that specializes in microbial identification and characterization, operating within the biotechnology industry. The company offers products and services that enable the characterization of microbial and mammalian cells, as well as the identification of a wide range of bacteria, yeast, and fungi. Biolog primarily serves sectors such as bioprocess and fermentation, environmental monitoring and quality control, brewing, probiotics, drug discovery and diagnostics, and basic research. It was founded in 1984 and is based in Hayward, California.

SpiderBiotech S.r.l.

Spider Biotech is a young and dynamic biotechnology company founded in 2005 with the aim of developing synthetic peptide therapeutics. nnAntimicrobial host-defense peptides have been recognized as an important part of innate immunity found throughout the evolutionary tree that defend against invading bacteria, viruses, and fungi through membrane or metabolic disruption. Inspired by natural antimicrobial peptides, Spider Biotech is developing a library of bioactive peptides and lipopeptides active against bacterial and viral infections. nSpiderBiotech's business strategy is to remain focused on the discovery and early-stage development of drug candidates and seek to establish partnerships with pharmaceutical companies for late-stage development and commercialization of its products. nnThe firm aims to become leader in developing peptide-based antiinfectives to address the urgent and global problem posed by resistance to conventional treatments. The Company is headquartered at the Bioindustry Park del Canavese (Turin, Italy).

Pulmotect Logo

Pulmotect is a bio-pharmaceutical company focused on developing products for severe respiratory diseases. The company's main offering is an inhaled therapeutic designed to stimulate the innate immune system in the lungs, providing protection against a range of viral, bacterial, and fungal pathogens. Pulmotect's products are primarily aimed at populations at risk of respiratory complications, such as individuals with COPD, asthma, and immunocompromised patients. It was founded in 2007 and is based in Houston, Texas.


REPLICor is a biopharmaceutical company developing first-in-class entry inhibitors for the treatment of hepatitis C (HCV) and prevention of HCV re-infection following liver transplantation. The company also targets the hepatitis B and influenza markets. The lead compound REP 9AC is a broad-spectrum antiviral having potent activity against HCV, HBV, influenza and other enveloped viruses. The compound is active by multiple routes of administration and is well tolerated. The company business strategy is to enter into alliances with major biopharmaceutical companies in order to further develop and market its product.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.